Jyong Biotech (NASDAQ:MENS) Trading Down 5% – Should You Sell?

Jyong Biotech Ltd. (NASDAQ:MENS) shares fell 5% during trading on Wednesday . The company traded as low as $1.70 and last traded at $1.72. 210,133 shares changed hands during trading, an increase of 298% from the average session volume of 52,794 shares. The stock had previously closed at $1.81.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jyong Biotech in a research report on Friday, May 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Jyong Biotech currently has a consensus rating of “Sell”.

Jyong Biotech Stock Down 5.0%

The company has a 50 day moving average of $2.23 and a two-hundred day moving average of $5.71.

Jyong Biotech (NASDAQ:MENS) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.02) earnings per share for the quarter.

Hedge Funds Weigh In On Jyong Biotech

Several institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC increased its stake in shares of Jyong Biotech by 209.4% in the 4th quarter. Millennium Management LLC now owns 40,258 shares of the company’s stock valued at $159,000 after purchasing an additional 27,245 shares in the last quarter. Man Group plc purchased a new stake in Jyong Biotech during the 4th quarter worth approximately $56,000. Jane Street Group LLC purchased a new stake in Jyong Biotech during the 4th quarter worth approximately $275,000. Geode Capital Management LLC increased its stake in Jyong Biotech by 19.6% during the 4th quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock worth $254,000 after buying an additional 10,538 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Jyong Biotech during the 4th quarter worth approximately $49,000.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.